HALOVAX - VAXCELERATE

WHAT IS VAXCELERATE?

VaxCelerate is a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) by HaloVax, LLC, a biopharmaceutical company and joint venture entity of Voltron Therapeutics, Inc. and Hoth Therapeutics, Inc. HaloVax plans to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection.

The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and remove infectious agents. The technology initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease, with the support of the Department of Defense (DoD). These same principles are being applied to developing a vaccine against the COVID-19 pandemic.

VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting. VaxCelerate offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.

VaxCelerate was created by Drs. Mark Poznansky, MD, PhD, and Jeffrey Gelfand, MD, who will continue to support its research and development, as COVID-19 has reached pandemic status. Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School.

DEVELOPMENT STATUS

The VaxCelerate product is currently in the early preclinical stage of development.

INVESTOR RELATIONS

Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.